Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 4 completed trials

    Completion Rate
    100%(4/4)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 1
    3
    75%
    Phase 3
    1
    25%

    Phase Distribution

    3

    Early Stage

    0

    Mid Stage

    1

    Late Stage

    Phase Distribution4 total trials
    Phase 1Safety & dosage
    3(75.0%)
    Phase 3Large-scale testing
    1(25.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    4 of 4 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(4)

    Detailed Status

    Completed4

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 13 (75.0%)
    Phase 31 (25.0%)

    Trials by Status

    completed4100%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_1

    Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

    NCT00357292
    completedphase_1

    Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

    NCT00357383
    completedphase_1

    Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

    NCT00357539
    completedphase_3

    Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

    NCT00357773

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00357292Phase 1

    Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

    Completed
    NCT00357383Phase 1

    Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

    Completed
    NCT00357539Phase 1

    Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

    Completed
    NCT00357773Phase 3

    Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    4